Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Stock Performance

NERV stock opened at $1.85 on Wednesday. The firm has a market cap of $12.94 million, a P/E ratio of -4.20 and a beta of 0.10. The firm’s fifty day moving average is $1.95 and its 200 day moving average is $2.25. Minerva Neurosciences has a 52 week low of $1.42 and a 52 week high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. As a group, analysts forecast that Minerva Neurosciences will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC raised its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the quarter. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 at the end of the most recent reporting period. Institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.